Table 1.
Select prospective phase II trials of multi-targeted tyrosine kinase inhibitors in RET rearranged non-small cell lung cancer.
| Agent | No. of patients | Objective response rate | Progression-free survival (median in months) | Median overall survival (median in months) | Dose reduction |
|---|---|---|---|---|---|
| Vandetanib18 | 19 | 9/19 (47%) | 4.7 | 11.1 | 10/19 (53%) |
| Vandetanib37 | 18 | 3/17 (18%) | 4.5 | 11.6 | 4/18 (22%) |
| Cabozantinib38 | 26 | 7/25 (28%) | 5.5 | 9.9 | 19/26 (73%) |
| Lenvatinib39 | 36 | 4/25 (16%) | 7.3 | NA | 16/25 (64%) |
| RXDX-10540 | 31 | 6/31 (19%)a | NA | NA | 19/62 (31%)a |
| Alectinib41 | 25 | 1/25 (4%)b | 3.4b | 19b | NA |
NE, not evaluable.
a
The response data are for patients with RET rearrangement who are RET tyrosine kinase inhibitor naïve. The dose reduction values are for the patients included in the phase Ib part of the trial treated at the recommended phase II dose.
b
Data are the efficacy results in the phase II part of the trial.